Ultragenyx gets first patient enrolled in Phase III trial of sialic acid extended release in GNE Myopathy
Ace-ER is designed to replace the deficient sialic acid substrate in patients with GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), a rare, progressive muscle-wasting disease.